Financial giants have made a conspicuous bullish move on Viking Therapeutics ( VKTX ). Our analysis of options history for Viking Therapeutics ( VKTX ) revealed 18 unusual trades.
Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $237,017, and 14 were calls, valued at $927,628.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $90.0 for Viking Therapeutics ( VKTX ) during the past quarter.
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's ( VKTX ) options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's ( VKTX ) whale trades within a strike price range from $5.0 to $90.0 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BULLISH | 7.4K | 1.0K | |||
| VKTX | CALL | TRADE | BEARISH | 139 | 20 | |||
| VKTX | CALL | SWEEP | BULLISH | 176 | 656 | |||
| VKTX | CALL | TRADE | BULLISH | 324 | 0 | |||
| VKTX | PUT | TRADE | NEUTRAL | 1.9K | 201 |
Viking Therapeutics Inc ( VKTX ) is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics ( VKTX ), it's now appropriate to focus on the company itself. We aim to explore its current performance.
Currently trading with a volume of 716,356, the VKTX's price is down by -0.79%, now at $62.85.
RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
Anticipated earnings release is in 36 days.
In the last month, 5 experts released ratings on this stock with an average target price of $95.0.
Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $90.
An analyst from BTIG persists with their Buy rating on Viking Therapeutics ( VKTX ), maintaining a target price of $100.
An analyst from Raymond James persists with their Outperform rating on Viking Therapeutics ( VKTX ), maintaining a target price of $115.
An analyst from HC Wainwright & Co. persists with their Buy rating on Viking Therapeutics ( VKTX ), maintaining a target price of $90.
In a cautious move, an analyst from Stifel downgraded its rating to Buy, setting a price target of $80.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics ( VKTX ), Benzinga Pro gives you real-time options trades alerts.
zpostcode
Recruit
weather
mreligion
Yellowpages
sport
constellation
shopping
name
game
directory
literature
Word
tour
furnish
Lottery
tftnews
lyrics
News
digital
car
dir
Edu
Finance
